| Methods | n = 45, 2 centres Allocation concealment: not described Baseline similarity: age (D), sepsis Blinding: caregivers Cointerventions: not described Withdrawals: treatment (5/22); control (2/23) Losses to follow‐up: none |
|
| Participants | Inclusions: bilateral CXR infiltrates, noncardiogenic pulmonary edema, PaO2 < 80 mmHg with Fi02 at least 0.4 Exclusions: history of pulmonary disease or pulmonary trauma |
|
| Interventions | IV acyclovir, 5 mg/kg daily for 18 days or until end of mechanical ventilation, or placebo | |
| Outcomes | Mortality: RR 1.10 (95% CI 0.54 to 2.22), based on data from 38 patients Duration of ventilation: MD 6.0 days (95% CI ‐4.4 to 16.4) Adverse events (any): none |
|
| Notes | ||
| Risk of bias | ||
| Bias | Authors' judgement | Support for judgement |
| Allocation concealment (selection bias) | Unclear risk | B ‐ Unclear |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.